Edition:
United Kingdom

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

10.25USD
21 Sep 2018
Change (% chg)

$-0.20 (-1.91%)
Prev Close
$10.45
Open
$10.40
Day's High
$10.65
Day's Low
$10.05
Volume
328,238
Avg. Vol
91,806
52-wk High
$21.35
52-wk Low
$8.62

Latest Key Developments (Source: Significant Developments)

Epizyme Reports Q2 Loss Per Share $0.42
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Epizyme Inc ::EPIZYME REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 LOSS PER SHARE $0.42.Q2 REVENUE $12 MILLION VERSUS $10 MILLION.Q2 REVENUE VIEW $538,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.  Full Article

Epizyme Provides Update Regarding Tazemetostat Clinical Program
Monday, 23 Apr 2018 

April 23 (Reuters) - Epizyme Inc ::EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM.U.S.-BASED ENROLLMENT OF NEW PATIENTS INTO TAZEMETOSTAT CLINICAL TRIALS IS TEMPORARILY ON HOLD.PATIENTS ON STUDY WHO HAVE NOT EXPERIENCED DISEASE PROGRESSION MAY CONTINUE TO RECEIVE TAZEMETOSTAT.EPIZYME HAS BEGUN DEVELOPING MODIFICATIONS TO ADDRESS PARTIAL CLINICAL HOLD.CO WILL NEED TO CONFIRM ALIGNMENT WITH FDA IN ORDER TO RESUME U.S. ENROLLMENT.EPIZYME -U.S. FDA ISSUED PARTIAL CLINICAL HOLD AFFECTING NEW ENROLLMENT OF PATIENTS WITH GENETICALLY DEFINED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES.PARTIAL CLINICAL HOLD WAS INITIATED FOLLOWING A SAFETY REPORT, SUBMITTED BY EPIZYME TO FDA AND OTHER REGULATORY AUTHORITIES.EPIZYME-REPORT WAS REGARDING A PATIENT WITH ADVANCED POORLY DIFFERENTIATED CHORDOMA IN PHASE 1 PEDIATRIC STUDY WHO DEVELOPED SECONDARY T-CELL LYMPHOMA.PATIENT WHO DEVELOPED A SECONDARY T-CELL LYMPHOMA HAS NOW DISCONTINUED TAZEMETOSTAT AND IS BEING TREATED FOR T-CELL LYMPHOMA.  Full Article

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article

BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49

* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES